

ClinicalTrials.gov: Oversight and Compliance at a Diverse Academic Research Center

Melanie Chladny, University of Michigan Medical School

Linda Mendelson, University of Michigan Rogel Cancer Center



Outline



- Structural challenges of a university with a diverse research portfolio and large cancer research center
- Oversight processes, compliance tracking mechanisms, and reporting tools
- Best practices & tips to pro-actively manage ClinicalTrials.gov records
- Growing influence of ClinicalTrials.gov
- Adapting to ongoing regulatory and policy change

Poll



How many of our audience members come from:

- a large university (more than 3 schools or colleges)?
- a cancer center?
- the federal government?



3

University of Michigan



- # 1 U.S. public university in research and development expenditures¹ : \$1.55 billion²
- 63,177 Students Enrolled³
- 19 Schools & Colleges
- 170 departments & divisions
- 6 research institutes
- 3 Hospitals & <125 Health Clinics / Centers
- 2.4 million patient visits in 2018⁴



1. https://ncesdata.nsf.gov/herd/2017/html/herd2017_dst_36.html


2. <https://www.research.umich.edu/research-u-m/office-research>

3. <https://2018.annualreport.umich.edu/>

4. <https://umich.edu/facts-figures/>

4

Research Diversity at University of Michigan



- 3 campuses
- University and Academic Medical Center
- Medical, Science, Social Research
- Some faculty have joint appointments with VA
- Rogel Cancer Center & Oncology Clinical Trial Support Unit
- Clinical Trial Support Office & Clinical Trial Support Units & new Clinical Research Management Team
- Michigan Institute for Clinical & Health Research (MICHHR)

ClinicalTrials.gov Implication: *diverse research input into a very structured system*

5

ClinicalTrials.gov at Michigan




- 2 organizational ClinicalTrials.gov accounts:

- Rogel Cancer Center
 - Cancer Trials
- University of Michigan group structure
 - 14 out of 19 Schools
 - Dearborn & Flint Campuses
 - UM Transportation Research Institute

- <1,160 user accounts
- 50 administrators
- <1,200 Records

University of Michigan's ClinicalTrials.gov Records




6

Regulatory Oversight for Human Subjects Research



University of Michigan Office of Research (UMOR)

Office of Research Compliance Review (ORCR)



- School of Dentistry
- School of Education
- School of Engineering
- School of Information
- Institute for Social Research (ISR)
- School of Kinesiology
- College of Literature, Science, and the Arts
- School of Medicine
- School of Nursing
- School of Pharmacy
- School of Public Health
- Ross Business School
- School for Environment and Sustainability (SEAS)
- School of Social Work
- Dearborn
- Flint
- University of Michigan Transportation Research Institute (UMTRI)


7

Regulatory Oversight for ClinicalTrials.gov



University of Michigan Office of Research (UMOR)

Office of Research Compliance Review (ORCR)



8

University of Michigan Rogel Cancer Center



- Rogel Cancer Center is a National Cancer Institute (NCI)-designated comprehensive cancer center
- Awarded the NCI P30 Cancer Center Support Grant (CCSG) since 1988
- The Support Grant funds cancer research infrastructure and enhances the center's ability to fund numerous research projects



9



Oncology Clinical Trial Support Unit (O-CTSU)




The O-CTSU serves as the centralized administrative core for clinical research conducted by investigators at the Rogel Cancer Center

- Through the O-CTSU, the Rogel Cancer Center provides services to support U-M's NCI oversight and reporting obligations
- O-CTSU facilitates data reporting required by NCI's Cancer Center Support Grant (CCSG) and Clinical Trials Reporting Program (CTRP)
- O-CTSU is also responsible for ClinicalTrials.gov oversight and reporting for investigator-initiated trials that are sponsored by UM


10



Rogel Cancer Center Process – ClinicalTrials.gov Reporting



Rogel Cancer Center Process – Data Reporting



Clinical Trials Support Units (CTSU)





15

New Centralized ClinicalTrials.gov Registration Service



- CTSU refers new Medical School Investigator-Initiated Clinical Trials to MICHHR Clinical Research Management Team (CRM Team)
- Includes:
 - Protocol review
 - Evaluation of primary and secondary outcome measures
 - Registration on ClinicalTrials.gov
 - General guidance and notifications to help manage ongoing obligations (i.e. annual updates)
 - Consultations with the Office of Regulatory Affairs for interpretation of federal regulations and policies

MICHHR CRM Team now registers about 2/3 of all new Med School clinical trials and expected to continue to increase



Organizational Structure & Impact on ClinicalTrials.gov Oversight



Will record management be centralized or decentralized?

	Rogel Cancer Center (O-CTSU)	Other Schools	Med School Studies	Med School CRM Trials
Model	Centralized	Decentralized, with centralized support	Decentralized, with centralized support	Centralized registration
Reason	Overlaps with some of the NCI CCSG reporting responsibilities	PI autonomy & accountability	PI autonomy & accountability	Improve quality and efficiency
Responsible Party	Institution / Sponsor	PI	PI	PI
Registration	Completed by Oncology Clinical Trial Support Unit (O-CTSU) w/content approved by PI	Completed by Study Team with assistance available from ORCR	Completed by Study Team with assistance available from Regulatory Affairs	Completed by MICHRCRM with input from Study Team
Maintenance	O-CTSU with input from Study Team or PI	Completed by Study Team with reminder from ORCR	Completed by Study Team with reminder from Regulatory Affairs	Completed by Study Team
Results Reporting	O-CTSU with input and approval from PI and statistician	Completed by Study Team with assistance from ORCR	Completed by Study Team with assistance from Regulatory Affairs	Completed by Study Team with Assistance from Regulatory Affairs
Escalation for ClinicalTrials.gov Non-Compliance	O-CTSU & Regulatory Affairs	ORCR	Regulatory Affairs	Regulatory Affairs

19

Best Practices & Tips to Pro-actively Manage ClinicalTrials.gov Records



20

Problems Prevention Using the Planning Report



Many errors are preventable

- Use the Planning Report to identify records that:
 - will be due to report results
 - require an annual update
 - are anticipated to start in the near future
 - are anticipated to finish in the near future
 - are funded by NIH
- Identify records that require outreach
- Conduct outreach with PI and study team



Challenge:

The system is only as good as the data entered. What other systems could we use as a cross-reference?

PRS Archive



Version	A	B	Date	Changes
1	<input checked="" type="radio"/>	<input type="radio"/>	December 15, 2008	Nothing (earliest Version on record)
2	<input type="radio"/>	<input type="radio"/>	April 16, 2009	Recruitment Status, Contacts/Locations, Study Status and References
3	<input type="radio"/>	<input type="radio"/>	July 8, 2009	Sponsor/Collaborators, Study Identification, Contacts/Locations and Study Status
4	<input type="radio"/>	<input type="radio"/>	July 14, 2009	Arms and Interventions, Study Status, Eligibility, Outcome Measures, Study Design and Study Description
5	<input type="radio"/>	<input type="radio"/>	August 17, 2009	Contacts/Locations and Study Status
6	<input type="radio"/>	<input type="radio"/>	September 28, 2009	Outcome Measures, Study Status and Contacts/Locations
7	<input type="radio"/>	<input type="radio"/>	January 4, 2010	Contacts/Locations and Study Status
8	<input type="radio"/>	<input type="radio"/>	January 27, 2010	Study Description, Contacts/Locations and Study Status
9	<input type="radio"/>	<input type="radio"/>	April 8, 2010	Contacts/Locations, Outcome Measures and Study Status
10	<input type="radio"/>	<input type="radio"/>	June 28, 2010	Study Status
11	<input type="radio"/>	<input type="radio"/>	August 11, 2010	Contacts/Locations and Study Status
12	<input type="radio"/>	<input type="radio"/>	September 28, 2010	Study Status and Contacts/Locations
13	<input type="radio"/>	<input type="radio"/>	December 29, 2010	Study Status, Study Design and Study Description
14	<input type="radio"/>	<input type="radio"/>	February 10, 2011	Recruitment Status, Study Status and Contacts/Locations
15	<input type="radio"/>	<input type="radio"/>	March 18, 2012	Sponsor/Collaborators, Study Status, Outcome Measures, Arms and Interventions, Study Design, Results and References
16	<input type="radio"/>	<input type="radio"/>	April 13, 2012	Outcome Measures, Baseline Characteristics, Reported Adverse Events, Study Status, More Information, Participant Flow and Study Description
17	<input type="radio"/>	<input checked="" type="radio"/>	May 10, 2016	Outcome Measures, Study Status, More Information, Baseline Characteristics and Sponsor/Collaborators

Record Verification:	December 2008	May 2016
Overall Status:	Unknown Status (Previously: Not yet reviewing)	Completed
Study Start:	December 2008	June 2009
Primary Completion:	November 2011 (Anticipated)	January 2011 (Actual)
Study Completion:	November 2011 (Anticipated)	January 2011 (Actual)
First Submitted:	December 15, 2008	December 15, 2008
First Submitted that Met QC Criteria:	December 15, 2008	December 15, 2008
First Posted:	December 17, 2008 (Estimate)	December 17, 2008 (Estimate)
Results First Submitted:		March 18, 2012
Results First Submitted that Met QC Criteria:		March 18, 2012
Results First Posted:		April 13, 2012 (Estimate)
Last Update Submitted that:	December 15, 2008	May 10, 2016

Historical view shows when any record was updated and how it was changed


- Edits or deletions will be displayed in **red**
- Additions will be displayed in **green**
- Hover over the "Recruitment Status" to see how the study's recruitment status changed

Use Quality Assurance processes to submit accurate, understandable content

Methods



- Training & education
- PRS Test
- ClinicalTrials.gov as a resource
- Outreach
 - Consultation & assistance
 - User instructions
 - Email templates
 - Reputation as helper
 - Customized approach
- Compliance
 - Tracking
 - Communication between administrators



The Growing Influence of ClinicalTrials.gov



Changes Impacting ClinicalTrials.gov



- The Common Rule
- Data Sharing

–  ICMJE INTERNATIONAL COMMITTEE OF MEDICAL JOURNAL EDITORS

–  pcori PATIENT-CENTERED OUTCOME RESEARCH INSTITUTE

–  NIH National Institutes of Health
Turning Discovery Into Health

– Implications for Informed Consent Documents

- NIH Policy
- Protocol Upload

Common Rule Informed Consent Requirement (46.116)



- Implementation date: January 21, 2019
- Applies **only to federally-conducted or supported clinical trials**
- Upload informed consents to either:
 - [ClinicalTrials.gov](https://clinicaltrials.gov) or
 - [regulations.gov](https://www.fda.gov/oc/ohrt/regulations.gov) Docket folder: HHS-OPHS-2018-0021
- Upload one IRB-approved version of informed consent document that has been used to enroll participants
- **After** the clinical trial is closed to recruitment
- Post consents **no later than 60 days** after the last study visit by any subject

The Michigan Way:

Upload informed consent document after study is closed to enrollment

Use a version that coheres with the final protocol

Challenge:

How can ClinicalTrials.gov help us to monitor for compliance?

Data Sharing



- Sharing data may be required to comply with federal funding or journal publisher guidelines
- Federal government expects results to be publically available
- Increase research impact and benefit the greater research community



Data Sharing – ICMJE



- Ethical obligation to share data
- Expect sharing de-identified individual-patient data (IPD)
- ICMJE now requires data sharing statement with manuscript
- Trials enrolling their first participants beginning in 2019 must disclose plan in ClinicalTrials.gov
 - Will IPD be available?
 - What data will be shared?
 - What documents will be available? (protocol, SAP, analytic code)
 - When will data be made available?
 - With whom?
 - For what types of analyses?
 - By what mechanism? (link or email)

http://www.icmje.org/news-and-editorials/data_sharing_june_2017.pdf
<http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html#two>

Data Sharing Statement Examples



	Example 1	Example 2	Example 3	Example 4	Example 5
Will individual participant data be available (including data dictionaries)?	Yes	Yes	Yes	No	Undecided
What data in particular will be shared?	All of the individual participant data collected during the trial, after deidentification.	Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).	Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).	Not available	Warning: Undecided does <u>not</u> meet ICMJE policy
What other documents will be available?	Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report, Analytic Code	Study Protocol, Statistical Analysis Plan, Analytic Code	Study Protocol	Not available	
When will data be available (start and end dates)?	Immediately following publication. No end date.	Beginning 3 months and ending 5 years following article publication.	Beginning 9 months and ending 36 months following article publication.	Not applicable	
With whom?	Anyone who wishes to access the data	Researchers who provide a methodologically sound proposal.	Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.	Not applicable	Not available
For what types of analyses?	Any purpose	To achieve aims in the approved proposal.	For individual participant data meta-analysis.	Not applicable	Not available
By what mechanism will data be made available?	All data will be shared	Proposals should be directed to xxx@yyy. To	Proposals may be submitted up to 36 mo	No data will be shared	Not available
		researchers will need to sign a data access agreement. Data are available for 5 years through a third party	publication. Information regarding accessing data may be found at (Link to b provided).		

The Michigan Way: Data Sharing



- ClinicalTrials.gov Administrators:
 - Work with investigators to register trial
 - Refer to specialized library team for data sharing questions
- Taubman Health Sciences Library Staff:
 - Consult with investigators on new ICMJE requirement
 - Help investigators identify funder-specific guidance/sharing requirements (if any)
 - Provide language for data sharing plan if requested and appropriate
 - Refer investigators to Data Office for Clinical & Translational Research if appropriate
 - Refer investigators to Inter-university Consortium for Political and Social Research or other repositories, if appropriate



<https://guides.lib.umich.edu/c.php?g=682739&p=6631773>
<https://www.icpsr.umich.edu/icpsrweb/content/datamanagement/dmp/framework.html>

PCORI Policy



- Data management and data sharing plan must be submitted as part of the protocol
 - Requires data sharing among PCORI-funded researchers
 - Differing specific requirements depending on the type of study
- IRB-approved informed consent form must document:
- all collected data will be de-identified
 - de-identified data will be used for secondary research purposes
 - de-identified data will be shared with other researchers



<https://www.pcori.org/about-us/governance/policy-data-management-and-data-sharing>

NIH Proposed Plan – Data Sharing



NIH sought public input to inform the development of a draft NIH policy:

- definition of scientific data
- requirements for data management and sharing plans
- optimal timing of implementation and how potential phasing could impact improvements in data infrastructure, resources, and standards

<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-014.html>
https://www.nlm.nih.gov/NIHbmic/nih_data_sharing_policies.html

Informed Consent Language & Data Sharing Expectations



- Patient-Centered Outcomes Research Institute (PCORI), NIH, and some journals will require de-identified data
- Are we required to disclose to participants the plan to share de-identified IPD?
- If we're sharing IPD, we have an ethical obligation to disclose
- We want consent for everything we're doing
- Recommended best practice: disclose in the informed consent

At present, we're using a consistent baseline across the institution



NIH & ClinicalTrials.gov



- All NIH-funded clinical trials that applied for funding and began after January 18, 2017 (regardless of study phase or type of intervention) must register and report results in ClinicalTrials.gov
- It is important to identify NIH funded studies because this impacts the PI's registration and reporting obligations
- Same requirements & timelines for NIH funded studies as ACTs
- NIH protocol templates for interventional and behavioral trials

Challenge:

How to trace indirectly funded trials?

<https://e-protocol.od.nih.gov/#/home>

<https://nexus.od.nih.gov/all/2019/04/01/the-protocol-template-for-behavioral-and-social-sciences-research-involving-humans-is-here/>

Protocol Upload



- Required for *any study that reports results*
- Upload at time of results submission
- Applies to Protocol and Statistical Analysis Plans
- Cover page
 - Official title
 - NCT
 - Version date
- Upload in PDF Archive (PDF A) format

The Michigan Way:

*Do not upload
protocol prior to
results reporting*



Implications of Protocol Upload



- Protocols **must** be suitable to share with the public
- FDA, grantors, and ICMJE may check for coherence
- Outcome measures in protocol and ClinicalTrials.gov must align
- Outcome measures must be clearly delineated in the protocol as either primary, secondary, or exploratory
- Outcome measures not identified as exploratory or other will be considered secondary and be required to report results (42 CFR 11.48(a)(5))
- Protocols and Informed Consent documents should cohere (applicable to federally funded trials)

How We Adapt to Change



37

Keeping Up With Change



Compliance means understanding what laws & policies apply to you, and following them



Challenges:

Evolving laws, policy, technology, standards, scope, equate to a moving target!

Different parts of the organization respond differently and at different paces

What Works for Us



- Monitor government websites (Federal Register, FDA, NIH)
- Subscribe to federal newsletters, news sources, and free webinars
- Meet regularly with counterparts to coordinate initiatives
- Develop relationship with other teams to develop organizational capacity as regulatory & policy changes arise
- Regulatory journals
- ClinicalTrials.gov articles and website
- Communicate regularly with external network

Challenges:

Reaching all PIs and study coordinators about changes that affect them

Finding the time to do it all!

ClinicalTrials.gov Taskforce



https://ctrtaskforce.org

Clinical Trials Registration and Results Reporting Taskforce

HOW TO JOIN | CONTACT

HOME ABOUT CALENDAR RESEARCH RESOURCES FAQs



The Clinical Trials Registration and Results Reporting Taskforce is a national consortium of members of academic medical centers, universities, hospitals, and non-profit organizations focused on the implementation of domestic clinical trials registration and results reporting requirements in the ClinicalTrials.gov public repository. The objectives of the group are to identify best practices, develop solutions and tools for regulatory support and investigators, and serve as a communication forum.

Do you have a topic that you would like to discuss at an upcoming taskforce meeting? Please email Sarah or Tony.

How to Join

Interested in joining the Taskforce?

Read more at our Membership webpage!

Next Meeting

Please join us at our next Taskforce meeting on **Thursday, May 16, 2019 from 1-2pm EST.**

Looking forward to presentations from An-Wen Chan (SPIRIT), Deb Zarin (MRCT), and Lauren Hartsmith (OHRP).

40

Summary



- For our large, diverse institution, one size does **not** fit all
- Change is constant

<u>Internal</u>	<u>External</u>
<ul style="list-style-type: none"> • Systems • Processes • Experience • Strategies 	<ul style="list-style-type: none"> • Expectations (e.g. transparency) • Regulations • Policies • Systems



- What's enhanced our success:
 - Best use of available resources
 - Coordination and planning
 - Communication
 - Relationships

designed by freepik.com

41

Questions?